Summary

Revises the federal prohibition on buying or selling human fetal tissue by defining what counts as “valuable consideration.” The bill lists specific kinds of payments, fee waivers, loan cancellations, free or reduced services, transfers, and reimbursements tied to tissue handling that will be treated as prohibited consideration. The change is purely definitional and does not create new funding or programs. It affects hospitals, researchers, tissue procurement organizations, and potential tissue donors by clarifying which financial or in‑kind transfers fall within the ban on sale or transfer of fetal tissue.

• Amends the federal definition of "valuable consideration" in the ban on sale/transfer of human fetal tissue.
• Specifies six categories of payments and in-kind transfers that qualify as prohibited consideration.
• Covers direct payments, gifts/honoraria, waived or reduced fees, canceled debts, free/reduced services, and payments tied to tissue handling (transport, processing, storage, etc.).
• Does not create new funding, programs, or change existing penalties in the provided text.
• Applies to hospitals, tissue procurement organizations, researchers, and healthcare providers involved with fetal tissue.
• May require changes to billing, reimbursement, and in‑kind exchange practices to maintain compliance.
• No effective date or transition rules are included in the amendment text.